18-deoxyaldosterone: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 21125567 |
| CHEMBL ID | 2373953 |
| SCHEMBL ID | 11597863 |
| MeSH ID | M0073866 |
| Synonym |
|---|
| 21-hydroxy-11beta,18-oxido-4-pregnene-3,20-dione |
| (11beta)-11,18-epoxy-21-hydroxypregn-4-ene-3,20-dione |
| 18-deoxyaldosterone |
| 2507-88-2 |
| unii-s4yt68r2xr |
| s4yt68r2xr , |
| CHEMBL2373953 |
| SCHEMBL11597863 |
| (1r,2s,5s,6s,14r,15s,16s)-2-(2-hydroxyacetyl)-14-methyl-17-oxapentacyclo[14.2.1.01,5.06,15.09,14]nonadec-9-en-11-one |
| progesterone, 11.beta.,18-epoxy-21-hydroxy- |
| (11.beta.)-11,18-epoxy-21-hydroxypregn-4-ene-3,20-dione |
| pregn-4-ene-3,20-dione, 11,18-epoxy-21-hydroxy-, (11.beta.)- |
| pregn-4-ene-3,20-dione, 11.beta.,18-epoxy-21-hydroxy- |
| DTXSID30947934 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " In each instance, receptor affinity was diminished by 1,2 unsaturation, but this effect was offset by the greater bioavailability of the delta 1 derivatives on oral administration." | ( Orally active mineralocorticoid agonists and antagonists: delta 1-derivatives of aldosterone and 18-deoxyaldosterone. Adam, WR; Funder, JW; Ulick, S, 1981) | 0.48 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID126432 | Relative binding affinity against Mineralocorticoid receptor in Male Sprague-Dawley rats | 1987 | Journal of medicinal chemistry, Sep, Volume: 30, Issue:9 | Aldosterone antagonists. 2. Synthesis and biological activities of 11,12-dehydropregnane derivatives. |
| AID126129 | In vivo relative Mineralocorticoid activity in Male Sprague-Dawley rats was determined;ND = no data | 1987 | Journal of medicinal chemistry, Sep, Volume: 30, Issue:9 | Aldosterone antagonists. 2. Synthesis and biological activities of 11,12-dehydropregnane derivatives. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.37) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||